Washington, DC – The Certified Principal Investigator (CPI®) credential is integrated into Investigator Databank, making this mark of qualification of clinical trial investigators visible to five major pharmaceutical companies.
The CPI® credential is held by more than 1,000 clinical trial investigators around the world. This unique designation is awarded to clinical trial investigators who have demonstrated proficiency of specific knowledge and job-related skills by passing a standardized Association of Clinical Research Professionals (ACRP) certification exam, independently administered by the Academy of Clinical Research Professionals (Academy).
"We applaud integration of the CPI® credential into Investigator Databank, whose members are some of the world's largest pharmaceutical companies. We believe ACRP's certification programs are fast becoming an industry standard for recognizing excellence in clinical research, and we are pleased to see this included by Investigator Databank," says Jim Kremidas, ACRP Executive Director. "Sponsors looking for qualified investigators through Investigator Databank can now seek out the CPI® credential specifically and be confident in the qualifications of investigators holding this distinguished credential."
"Investigator Databank are very proud to partner with ACRP to integrate the CPI® credential, allowing visibility of the qualification to the five member companies. By ensuring that an investigator's research qualifications are visible to pharmaceutical companies, ACRP are making the clinical research process more efficient both for sponsors seeking investigators for clinical trials, and for their members," said Elisa Cascade, President of Data Solutions at DrugDev, the third-party host of Investigator Databank.
About Investigator Databank
The Investigator Databank (www.investigatordatabank.org) is a global collaboration between Janssen, Lilly, Merck, Pfizer, and Novartis to share investigator information that each company has on file with one another. Investigator Databank aims to reduce administrative burden for investigators and to increase visibility of qualified investigators to research sponsors.
About ACRP
ACRP supports clinical research professionals through membership, training and development, and certification. Founded in 1976, ACRP is a Washington, DC-based nonprofit organization with more than 13,000 members who work in clinical research in more than 70 countries. ACRP's vision is that clinical research is performed ethically, responsibly, and professionally everywhere in the world. ACRP's mission is to promote excellence in clinical research. www.acrpnet.org
About the Academy
The Academy of Clinical Research Professionals is an independent affiliate of ACRP. The Academy, a nonprofit 501(c)6, is solely responsible for the governance, development and administration of ACRP's certification programs. Its mission is to promote and maintain high standards and best practices of clinical research by recognizing those professionals who demonstrate a well-defined competency through valid and reliable credentialing programs. Academy trustees are elected by individuals holding the CCRA®, CCRC®, or CPI® designation. To date, more than 29,500 individuals in 60 countries have achieved certification through the Academy. www.acrpnet.org/certification
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.